secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telesis Bio Inc. (—)
CIK:        0001850079
Form:       8-K
Filed at:   2023-06-09T23:59:59+00:00
Accession:  0001193125-23-164515
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 3.02, 3.03, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Telesis Bio closes $28M private placement of preferred stock and warrants; appoints Paul Meister to board
--------------------------------------------------------------------------------

- Initial gross proceeds of $28.0M from private placement of redeemable convertible preferred stock and warrants.
- Warrants could provide up to $46.2M in additional proceeds if cash exercised.
- Financing led by Novalis LifeSciences; includes participation from Northpond Ventures, BroadOak, and CEO affiliate M-185 Corp.
- Paul Meister, partner at Novalis LifeSciences, appointed to board effective June 5, 2023, expanding board from 7 to 8 directors.
- Proceeds to be used for general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850079/000119312523164515/0001193125-23-164515-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850079/000119312523164515/d463439d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-164515

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer